Having demonstrated that low IGFBP7 expression is predictive of a benefit of adding ganitumab to chemotherapy in neoadjuvant breast cancer treatment and that high IGFBP7 expression predicts poor outcome, we next sought to determine if IGFBP7 expression was related to other breast cancer characteristics. Here, IGFBP7 is linked to breast cancer.